Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System

Clin Infect Dis. 2021 Oct 5;73(7):e1436-e1442. doi: 10.1093/cid/ciaa1732.


Background: Acute bacterial skin and skin structure infections (ABSSSIs) are common infectious diseases that cause a significant economic burden on the healthcare system. This study aimed to compare the cost-effectiveness of dalbavancin vs standard of care (SoC) in the treatment of ABSSSI in a community-based healthcare system.

Methods: This was a retrospective study of adult patients with ABSSSI treated with dalbavancin or SoC during a 27-month period. Patients were matched based on age and body mass index. The primary outcome was average net cost of care to the healthcare system per patient, calculated as the difference between reimbursement payments and the total cost to provide care to the patient. The secondary outcome was proportion of cases successfully treated, defined as no ABSSSI-related readmission within 30 days after the initiation of treatment.

Results: Of the 418 matched patients, 209 received SoC and 209 received dalbavancin. The average total cost of care per patient was greater with dalbavancin vs SoC ($4770 vs $2709, P < .0001). The average reimbursement per patient was $3084 with dalbavancin vs $2633 SoC (P = .527). The net cost, calculated as revenue minus total cost, was $1685 with dalbavancin vs $75 with SoC (P = .013). The overall treatment success rate was 74% with dalbavancin vs 85% with SoC (P = .004).

Conclusions: Dalbavancin was more costly than SoC for the treatment of ABSSSI, with a higher 30-day readmission rate. Dalbavancin does not offer an economic or efficacy advantage.

Keywords: acute bacterial skin and skin structure infections; antibiotics; dalbavancin; pharmacoeconomics.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Cost-Benefit Analysis
  • Delivery of Health Care
  • Humans
  • Retrospective Studies
  • Skin Diseases, Bacterial* / drug therapy
  • Standard of Care*
  • Teicoplanin / analogs & derivatives
  • Teicoplanin / therapeutic use


  • Anti-Bacterial Agents
  • Teicoplanin
  • dalbavancin